IS ACROMEGALY A HYPERCOAGULABLE CONDITION? CASE REPORTS AND REVIEW OF THE LITERATURE
Abstract
Introduction: Cardiovascular complications are a major cause of morbidity and mortality in patients with uncontrolled acromegaly. However, there are no published reports of an increased risk of venous thromboembolism (VTE) in such patients. We report three patients with uncontrolled acromegaly who presented with VTE.
Clinical Cases: A 52-year-old male with uncontrolled acromegaly despite transsphenoidal (TSP) surgery and medical therapy presented in 2012 with acute chest pain and shortness of breath that was later con rmed as secondary to pulmonary embolism. A 44-year-old male immigrant, previously treated for acromegaly with radiation therapy alone, in 1992, in his native country, was referred to our centre in 2006 for acromegaly which remained uncontrolled despite medical therapy until 2009 when he achieved remission through TSP surgery. He had several episodes of VTE between 2008 and 2010. A 69-year-old male with uncontrolled acromegaly for 28 years despite two surgical resections and radiation therapy in 1986 and 1992, as well as continuous medical therapy, presented with VTE of the right axillary vein and bilateral pulmonary emboli in 2011. A thrombophilia screen in case 1 showed mild protein S de ciency, case 2 was homozygous for factor V Leiden (FVL) mutation and case 3 was heterozygous for FVL. Extensive investigations revealed no evidence of malignancy and echocardiography showed preserved ejection fraction in all three patients.
Conclusion: Patients with uncontrolled acromegaly may be at increased risk of VTE. However, larger studies are required to further assess this association and determine the underlying cause.
Key words: Acromegaly, pituitary tumours, thromboembolism
References
Lombardi G, Galdiero M, Auriemma RS, et al. Acromegaly and the cardiovascular system. Neuroendocrinology 2006; 83:211-7.
Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom acromegaly study group. J Clin Endocrinol Metab 1998;83:2730-4.
Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, et al. Elevated brinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 1997;46:69-74.
Erem C, Nuhoglu I, Kocak M, et al. Blood coagulation and fibrinolysis in patients with acromegaly: Increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Endocrine 2008; 33:270-6.
Wildbrett J, Hanefeld M, Fücker K, et al. Anomalies of lipoprotein pattern and brinolysis in acromegalic patients: Relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 1997;105:331-5.
Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010;137:1382-90.
Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypo brinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010;116:113 21.
Foy P, Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med 2009;11:114-28.
Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood 1995;85:1504-8.
Young A, Chapman O, Connor C, et al. Thrombosis and cancer. Nat Rev Clin Oncol 2012;9:437-49.
Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: A national, population-based cohort study. Br J Cancer 2004; 91:92-5.
Terzolo M, Reimondo G, Gasperi M, et al. Colonoscopic screening and follow-up in patients with acromegaly: A multicenter study in Italy. J Clin Endocrinol Metab 2005; 90:84-90.
dos Santos MC, Nascimento GC, Nascimento AG, et al. Thyroid cancer in patients with acromegaly: A case-control study. Pituitary 2013;16:109-14.
Kauppinen-Mäkelin R, Sane T, Välimäki MJ, et al. Increased cancer incidence in acromegaly a nationwide survey. Clin Endocrinol (Oxf) 2010;72:278-9.
Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009;94:1509-17.
Katznelson L, Atkinson JL, Cook DM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract 2011; 17 Suppl 4:1-44.
Melmed S, Kleinberg D. Pituitary Masses and Tumors. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg M. Williams Textbook of Endocrinology. 12th ed. Philadelphia,PA: Elsevier; 2011. p. 229-90.
Brada M, Ford D, Ashley S, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ 1992;304:1343-6.
Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: A retrospective, case-control study. J Clin Epidemiol 2001; 54:810-6.
Dean SM, Abraham W. Venous thromboembolic disease in congestive heart failure. Congest Heart Fail 2010;16:164-9.
Muller AF, Leebeek FW, Janssen JA, et al. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: Implications for the pathogenesis of atherosclerosis in GH de ciency. J Clin Endocrinol Metab 2001;86:5165-71.
van der Lely AJ, Biller BM, et al. Long-term safety of pegvisomant in patients with acromegaly: Comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97:1589-97.
Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011;13:1-6.
Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
